Methotrexate(Aldeyra Therapeutics)

甲氨蝶呤玻璃体注射剂（Aldeyra Therapeutics）

Report date: 2026/04/08 15:32:49

Base Information

Drug NameMethotrexate(Aldeyra Therapeutics)
Drug Alias NameADX-2191
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThymidylate synthase inhibitorsDihydrofolate reductase inhibitors
TargetsDihydrofolate reductaseThymidylate synthase
Therapy Area/IndicationsPrimary vitreoretinal lymphomaVitreoretinopathy, ProliferativeRetinitis Pigmentosa +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesAldeyra Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAldeyra Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrimary vitreoretinal lymphomaVitreoretinopathy, ProliferativeRetinitis Pigmentosa +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A